CompletedNot applicableNCT02396238
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cytori Therapeutics
- Principal Investigator
- Steven Kesten, MDCytori Therapeutics
- Intervention
- Celution Device(device)
- Enrollment
- 88 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2015 – 2018
Study locations (19)
- Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, United States
- Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
- Arthritis Associates of Southern California, Los Angeles, California, United States
- UCLA David Geffen School of Medicine, Los Angeles, California, United States
- Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Northwestern University, Chicago, Illinois, United States
- Heartland Research Associates, Wichita, Kansas, United States
- Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Boston University Medical Center, Boston, Massachusetts, United States
- West Michigan Rheumatology, PLLC, Grand Rapids, Michigan, United States
- Center For Pharmaceutical Research, Kansas City, Missouri, United States
- Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
- Hospital for Special Surgery, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02396238 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University